Optimization of Cardiac Imaging in Women With Early-Stage Breast Cancer

Pilot Study for Optimization of Cardiac Imaging in Women With Early-Stage Breast Cancer

The purpose of this study is to determine whether a personalized, risk-stratified surveillance strategy can safely reduce unnecessary cardiac imaging while preserving early detection of treatment-related cardiotoxicity in women with breast cancer (BC) receiving HER2-targeted therapy (HER2-TT).

Inclusion Criteria:

• Female sex, age 18-79 years.
• Histologically confirmed HER2-positive BC scheduled for ≈12 months of adjuvant HER2-TT
• Baseline LVEF ≥ 55 % by 2-D echocardiography.
• Ability to provide informed consent.

Exclusion Criteria:

• Prior HF, myocardial infarction, or cardiomyopathy.
• Atrial fibrillation or significant valvular heart disease.
• Cumulative anthracycline dose ≥ 250 mg/m².
• Pregnancy or lactation.
• Inability to comply with study procedures.